Journal: Experimental and Therapeutic Medicine

Article Title: Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells

doi: 10.3892/etm.2018.6925

Figure Lengend Snippet: Inhibitory effect of propranolol, vincristine and bevacizumab in HUVECs and BJs. Cell viability determined by MTT assay is presented as a function propranolol in (A) HUVECs and (B) BJs, vincristine in (C) HUVECs and (D) BJs, and bevacizumab in (E) HUVECs and (F) BJs. *P<0.05; **P<0.01; and ***P<0.001 vs. untreated (0 µg/ml). HUVEC, human umbilical vein endothelial cell; BJ, CRL-2522 human normal fibroblast.

Article Snippet: BJs were cultured at 37°C in a 5% CO 2 incubator in Eagle's Minimum Essential medium (MEM, Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and HUVECs were cultured in Endothelial Cell Growth medium (ECG, Cell Applications, Inc., San Diego, CA, USA); media were supplemented with 10% fetal calf serum (Sigma-Aldrich; Merck KGaA).

Techniques: MTT Assay

Journal: Experimental and Therapeutic Medicine

Article Title: Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells

doi: 10.3892/etm.2018.6925

Figure Lengend Snippet: Inhibitory effect of propranolol plus vincristine, propranolol plus bevacizumab and vincristine plus bevacizumab in HUVECs and BJs. Cell viability determined by MTT assay is presented as a function of drug concentration, with varying propranolol plus 10 µg/ml vincristine in (A) HUVECs and (B) BJs, with varying propranolol plus 100 mg/ml bevacizumab in (C) HUVECs and (D) BJs, and with varying vincristine plus 100 mg/ml bevacizumab in (E) HUVECs and (F) BJs. *P<0.05; **P<0.01; and ***P<0.001 vs. untreated (0 µg/ml). HUVEC, human umbilical vein endothelial cell; BJ, CRL-2522 human normal fibroblast.

Article Snippet: BJs were cultured at 37°C in a 5% CO 2 incubator in Eagle's Minimum Essential medium (MEM, Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and HUVECs were cultured in Endothelial Cell Growth medium (ECG, Cell Applications, Inc., San Diego, CA, USA); media were supplemented with 10% fetal calf serum (Sigma-Aldrich; Merck KGaA).

Techniques: MTT Assay, Concentration Assay

Journal: Experimental and Therapeutic Medicine

Article Title: Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells

doi: 10.3892/etm.2018.6925

Figure Lengend Snippet: Apoptosis evaluation of HUVECs treated with propranolol, vincristine and bevacizumab and combinations of the drugs. Representative images of flow cytometry-based apoptosis evaluation of HUVECs (A) untreated or treated with (B) propranolol (50 µg/ml), (C) vincristine (10 µg/ml), (D) bevacizumab (50 µg/ml), (E) propranolol (50 µg/ml) plus vincristine (10 µg/ml), (F) propranolol (50 µg/ml) plus bevacizumab (50 µg/ml), (G) vincristine (10 µg/ml) plus bevacizumab (50 µg/ml), and (H) propranolol (50 µg/ml) plus vincristine (10 µg/ml) plus bevacizumab (50 µg/ml). HUVECs, human umbilical vein endothelial cell; Q1, quadrant representative of early apoptosis; Q2, quadrant representative of late apoptosis; Q3, quadrant representative of viable cells; Q4, quadrant representative of dead cells.

Article Snippet: BJs were cultured at 37°C in a 5% CO 2 incubator in Eagle's Minimum Essential medium (MEM, Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and HUVECs were cultured in Endothelial Cell Growth medium (ECG, Cell Applications, Inc., San Diego, CA, USA); media were supplemented with 10% fetal calf serum (Sigma-Aldrich; Merck KGaA).

Techniques: Flow Cytometry

Journal: Experimental and Therapeutic Medicine

Article Title: Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells

doi: 10.3892/etm.2018.6925

Figure Lengend Snippet: Quantitative evaluation of apoptosis in HUVECs and BJs treated with propranolol, vincristine and bevacizumab and combinations of the drugs. Number early and late apoptotic and dead cells determined by flow cytometry using (A) HUVECs and (B) BJs treated with propranolol (50 µg/ml), vincristine (10 µg/ml) and bevacizumab (50 µg/ml) and combinations of the drugs. Values are per population of 10,000 cells. HUVEC, human umbilical vein endothelial cell; BJ, CRL-2522 human normal fibroblast; P, propranolol; V, vincristine; B, bevacizumab.

Article Snippet: BJs were cultured at 37°C in a 5% CO 2 incubator in Eagle's Minimum Essential medium (MEM, Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and HUVECs were cultured in Endothelial Cell Growth medium (ECG, Cell Applications, Inc., San Diego, CA, USA); media were supplemented with 10% fetal calf serum (Sigma-Aldrich; Merck KGaA).

Techniques: Flow Cytometry